Category Archives: Sofosbuvir

Australian duo find global consumers for Indian generic drugs

By Divya Rajagopal, The Economic Times | May 23, 2017 MUMBAI: Remember Ron the rodeo cowboy from the Oscar-winning film Dallas Buyers Club? The biopic portrayed the story of Ron Woodroof, an AIDS patient in the mid-1980s who signed up … Continue reading

Posted in Generics, Hepatitis C, Sofosbuvir, Uncategorized | Leave a comment

Better life through medicine—let’s leave no one behind

Source: http://www.thelancet.com The Lancet Commission on Essential Medicines Policies  rightfully addresses the need to guarantee access to essential medicines for all. However, we cannot achieve any real progress without acknowledging that the current patent-based business model and the way we … Continue reading

Posted in Delinkage, R&D, R&D, Sofosbuvir, TRIPS, TRIPS flexibilities, Uncategorized | Leave a comment

Hepatitis drug patent application opposed

A health advocacy group voiced its opposition Tuesday to a patent application for hepatitis C medicine, Sofosbuvir, filed with the Department of Intellectual Property’s Patent Office, which the group said was unjustified. If approved, the drug patent would bar fair … Continue reading

Posted in Hepatitis C, Patent Opposition, Sofosbuvir, Uncategorized | Leave a comment

Healthcare Groups Challenge Patents On Three New Hep-C Drugs In India

Source: Business World The patent challenges could remove barriers to production and distribution of affordable generic versions of direct-acting antiviral medicines, which are currently sold at very high prices Patient and healthcare aid groups, including I-MAK and Delhi Network of … Continue reading

Posted in Evergreening, Hepatitis C, Patent Opposition, Sofosbuvir, Uncategorized | Tagged , , | Leave a comment

Healthcare and patient groups oppose patents on crucial hepatitis C drugs

By Rupali Mukherjee, The Times of India  MUMBAI: Healthcare aid and patient groups have come together in patent courts to fight against “abusive strategies” of Big Pharma, to ensure access to affordable treatment in hepatitis C. The Initiative for Medicines, … Continue reading

Posted in Evergreening, Hepatitis C, Patent Opposition, Sofosbuvir, Uncategorized | Tagged , | Leave a comment

Flawed patents on hepatitis C drugs latest to be challenged in global push for access

Source: MSF Access Campaign New Delhi/New York, 14 February 2017–Five new challenges against patents on crucial new medicines to treat hepatitis C filed in India and Argentina are the latest in a global push to ensure access to affordable treatment. … Continue reading

Posted in Evergreening, Hepatitis C, Patent Opposition, Sofosbuvir, Uncategorized | Tagged , , | Leave a comment

Unavailability of Affordable Hepatitis C Treatments Threatening Malaysian Lives

The World Health Organization (WHO) recently reported that over one million people in low- and middle-income countries have been treated with a revolutionary new cure for hepatitis C since its introduction two years ago.

Posted in Hepatitis C, Sofosbuvir, Uncategorized | 1 Comment